T1	intervention 5 14	tamoxifen
T2	outcome 1887 1906	Event-free survival
T3	outcome 1591 1597	events
T4	iv-bin-abs 1603 1605	39
T5	cv-bin-abs 1617 1619	44
T6	outcome 1631 1651	locoregional relapse
T7	outcome 1661 1679	distant metastases
T8	outcome 1690 1716	metachronous breast cancer
T9	outcome 1726 1739	other tumours
T10	iv-bin-abs 1655 1657	10
T11	cv-bin-abs 1658 1659	8
T12	iv-bin-abs 1683 1685	14
T13	cv-bin-abs 1686 1688	16
T14	iv-bin-abs 1720 1721	4
T15	cv-bin-abs 1722 1724	10
T16	iv-bin-abs 1743 1745	11
T17	cv-bin-abs 1746 1748	10
T18	outcome 1480 1504	prematurely discontinued
T19	iv-bin-abs 1460 1470	Thirty-six
T21	total-participants 1014 1043	Four hundred and thirty-three
T22	intervention-participants 1087 1090	217
T23	control-participants 1102 1105	216
T25	age 389 403	35 to 75 years
T20	control 609 624	follow-up alone
T26	eligibility 405 553	operated more than 2 years previously for monolateral breast cancer without adjuvant TAM, with no signs of metastases and no contraindication to TAM
T24	outcome 1764 1800	ER-positive secondary breast cancers
T27	iv-bin-abs 1866 1867	1
T28	cv-bin-abs 1871 1873	10
T29	control 1092 1101	follow-up
